Recent data indicates that hepatic steatosis affects 38 % of the global adult population [1,2]. Metabolic dysfunction-associated steatotic liver disease (MASLD) [3,4] is the most common cause of chronic liver disease worldwide, with an all-cause mortality rate nearly double that of the general population [5]. Given the high prevalence of hepatic steatosis, non-invasive methods are greatly preferable for diagnosis and follow-up after treatment.